FDA Antiviral Division's Jolson Will Be Acting ORM Director Starting Nov. 6
Executive Summary
Antiviral Drug Products Division Director Heidi Jolson, MD, will take over as acting director of the Office of Review Management on Nov. 6.
You may also be interested in...
Priority Review Criteria Reassessment Called For In FDA Rezulin Report
FDA's criteria for assigning priority review status should be re-evaluated, a Center for Drug Evaluation & Research Quality Assurance Staff report on the review of Warner-Lambert's Rezulin suggests.
Priority Review Criteria Reassessment Called For In FDA Rezulin Report
FDA's criteria for assigning priority review status should be re-evaluated, a Center for Drug Evaluation & Research Quality Assurance Staff report on the review of Warner-Lambert's Rezulin suggests.
FDA Reproductive Division Deputy Is Ditropan XL Reviewer Shames
FDA has named Daniel Shames, MD, as deputy director of its Division of Reproductive & Urologic Drug Products.